[
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "< 5×10−2",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−2",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−3",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−3",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−4",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−4",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−5",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−5",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−6",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−6",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−7",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−7",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−8",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−8",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−9",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−9",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−10",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−10",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−11",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−11",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−12",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−12",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−13",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−13",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−14",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−14",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 5×10−15",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "about 10−15",
        "unit": "M",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "IGF-1R polypeptides or fragments or variants thereof",
        "protein_target_name": "IGF-1R",
        "binding_metric": "k(off)",
        "value": "less than or equal to 5×10−2",
        "unit": null,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nbinds to at least one epitope of IGF-1R or fragment or variant described above with an affinity characterized by a dissociation constant K<sub>D </sub>of less than about 5×10<sup>−2 </sup>M, about 10<sup>−2 </sup>M, about 5×10<sup>−3 </sup>M, about 10<sup>−3 </sup>M, about 5×10<sup>−4 </sup>M, about 10<sup>−4 </sup>M, about 5×10<sup>−5 </sup>M, about 10<sup>−5 </sup>M, about 5×10<sup>−6 </sup>M, about 10<sup>−6 </sup>M, about 5×10<sup>−7 </sup>M, about 10<sup>−7 </sup>M, about 5×10<sup>−8 </sup>M, about 10<sup>−8 </sup>M, about 5×10<sup>−9 </sup>M, about 10<sup>−9 </sup>M, about 5×10<sup>−10 </sup>M, about 10<sup>−10 </sup>M, about 5×10<sup>−11 </sup>M, about 10<sup>−11 </sup>M, about 5×10<sup>−12 </sup>M, about 10<sup>−12 </sup>M, about 5×10<sup>−13 </sup>M, about 10<sup>−13 </sup>M, about 5×10<sup>−14 </sup>M, about 10<sup>−14 </sup>M, about 5×10<sup>−15 </sup>M, or about 10<sup>−15 </sup>M.\na binding moiety binds IGF-1R polypeptides or fragments or variants thereof with an off rate (k(off)) of less than or equal to 5×10<sup>−2 </sup>"
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻²",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻²",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻³",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻³",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻⁴",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻⁴",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻⁵",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻⁵",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻⁶",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻⁶",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻⁷",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻⁷",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻⁸",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻⁸",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻⁹",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻⁹",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻¹⁰",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻¹⁰",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻¹¹",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻¹¹",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻¹²",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻¹²",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻¹³",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻¹³",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻¹⁴",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻¹⁴",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10⁻¹⁵",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VL",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10⁻¹⁵",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety (or binding molecule) comprising, consisting essentially of, or consisting of a VL encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (KₓD) no greater than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−2",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−2",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−3",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−3",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−4",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−4",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−5",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−5",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−6",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−6",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−7",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−7",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−8",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−8",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−9",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−9",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−10",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−10",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−11",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−11",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−12",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−12",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−13",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−13",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−14",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−14",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "5×10−15",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH",
        "protein_target_name": "IGF-1R",
        "binding_metric": "Kd",
        "value": "10−15",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety binding molecule comprising, consisting essentially of, or consisting of a VH encoded by one or more of the polynucleotides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−2",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−2",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−3",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−3",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−4",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−4",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−5",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−5",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−6",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−6",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−7",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−7",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−8",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−8",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−9",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−9",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−10",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−10",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−11",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−11",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−12",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−12",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−13",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−13",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−14",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−14",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−15",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VH polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−15",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of one or more of the VH polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−2",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−2",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−3",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−3",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−4",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−4",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−5",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−5",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−6",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−6",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−7",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−7",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−8",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−8",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−9",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−9",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−10",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−10",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−11",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−11",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−12",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−12",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−13",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−13",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−14",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−14",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "5×10−15",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "VL polypeptides",
        "protein_target_name": "IGF-1R polypeptide",
        "binding_metric": "Kd",
        "value": "10−15",
        "unit": "M",
        "raw_mentions": "In certain embodiments, the invention pertains to a binding moiety or binding molecule comprising, consisting essentially of, or consisting of a one or more of the VL polypeptides described above specifically or preferentially binds to an IGF-1R polypeptide or fragment thereof, or a IGF-1R variant polypeptide, with an affinity characterized by a dissociation constant (K<sub>D</sub>) no greater than 5×10<sup>−2 </sup>M, 10<sup>−2 </sup>M, 5×10<sup>−3 </sup>M, 10<sup>−3 </sup>M, 5×10<sup>−4 </sup>M, 10<sup>−4 </sup>M, 5×10<sup>−5 </sup>M, 10<sup>−5 </sup>M, 5×10<sup>−6 </sup>M, 10<sup>−6 </sup>M, 5×10<sup>−7 </sup>M, 10<sup>−7 </sup>M, 5×10<sup>−8 </sup>M, 10<sup>−8 </sup>M, 5×10<sup>−9 </sup>M, 10<sup>−9 </sup>M, 5×10<sup>−10 </sup>M, 10<sup>−10 </sup>M, 5×10<sup>−11 </sup>M, 10<sup>−11 </sup>M, 5×10<sup>−12 </sup>M, 10<sup>−12 </sup>M, 5×10<sup>−13 </sup>M, 10<sup>−13 </sup>M, 5×10<sup>−14 </sup>M, 10<sup>−14 </sup>M, 5×10<sup>−15 </sup>M, or 10<sup>−15 </sup>M."
    },
    {
        "molecule_name": "N-term. IGF-1R bispecific antibody",
        "protein_target_name": "sIGF-1R(1-903)",
        "binding_metric": "Kd",
        "value": "11",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\nAdditionally, there was more curvature (and more titration points) in the transition region for defining the affinity of the N-term. IGF-1R bispecific antibody to sIGF-1R(1-903). This enabled the measurement of an apparent equilibrium dissociation constant, K<sub>D</sub>, of 11 nM (FIG. 40D, Table 25).\nThe C-term. IGF-1R bispecific antibody demonstrated an incredibly strong enthalpy of binding (−54 kcal/mol, Table 25), \nThe N-term. IGF-1R bispecific antibody also showed a strong enthalpy (−43 kcal/mol, Table 25), \nTABLE 25Thermodynamic parameters for the binding of IGF-1R to theC06 and G11 Mabs ndividually and in combination as well asthe parameters for the binding of the C- and N-terminal IGF-1R bispecific antibodies measured using ITC.ΔH°−TΔSΔGK<sub>D</sub>Construct(kcal \n\nNote that the last line is a table header, but it seems to be the start of a table that would contain relevant data. If the full table is provided, more rows could be extracted."
    }
]